Real-World Comparison of Adherence and Persistence between Glucagon-like Peptide-1 Receptor Agonist (GLP-1) and Sodium-Glucose Cotransporter 2 (SGLT-2) in Patients with Type 2 Diabetes (T2D)

Speaker(s)

Risebrough N1, Yu X2, Edwards A2, Shen Y2, Hunger M3, Lawrence A2
1ICON plc, Toronto, ON, Canada, 2Symphony Health, ICON plc, Blue Bell, PA, USA, 3ICON plc, Frankfurt, Germany

OBJECTIVES: To assess adherence and discontinuation of glucagon-like peptide-1 (GLP-1) and sodium-glucose cotransporter-2 (SGLT-2) among adult type-2 diabetes mellitus (T2D) patients in the United States based on real-world claims and linked clinical data from ICON’s Symphony Health Integrated Dataverse (IDV).

METHODS: Adults with T2D, with ≥ 1 year of follow-up, naïve to the drug class and who initiated a newer GLP-1 or SGLT-2 (index date) between 2017 to 2021 were identified using IDV. A subgroup of patients was selected that matched the inclusion criteria and had an HbA1C ≥ 7% within 60 days of the index date.

IDV pharmacy and medical claims and lab data were integrated into a single enriched dataset using tokenization. Adherence was measured by the proportion of days covered (PDC) ≥ 80%. Persistence was measured as time from index date to discontinuation and as a proportion on treatment at 90, 180, 360 and 720 days.

RESULTS: In IDV, 1,789,151 and 1,953,547 patients newly initiated a GLP-1 or SGLT-2 in the main cohort and 165,758 and 233,222 patients respectively met the HbA1C criteria (subgroup).

Starting a GLP-1 or SGLT-2, the subgroup population was primarily female (51% and 56%, respectively) with a mean age of 59.0 and 59.7 years, respectively. HbA1C at the index date (9.3% vs 9.1%, respectively) and years of follow-up (3.9 vs 4.1 years, respectively) were similar.

PDC was higher for SGLT-2 subgroup (mean 0.784, SD 0.258) compared to GLP-1 (mean 0.744, SD 0.270), p < 0.001. In the patient subgroup, GLP-1 and SGLT-2 persistence at 360 (48.1% vs 46.8%, respectively) and 720 days (31.9% vs 31.4%) were similar.

CONCLUSIONS: Real-world data suggest greater adherence to SGLT-2 than GLP-1 treatment, however overall persistence data over two years was similar. Further investigation of effectiveness and reasons of low persistence are warranted, of which this large dataset may be useful.

Code

SA33

Topic

Patient-Centered Research, Study Approaches

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Diabetes/Endocrine/Metabolic Disorders (including obesity), Drugs